Roferon-a 3miu    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
56Behcet disease1

56. Behcet disease    [ 68 clinical trials,   87 drugs,   (DrugBank: 31 drugs),   36 drug target genes,   113 drug target pathways]
Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 68 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005390-36-GB
(EUCTR)
17/02/201631/12/2015BIO BEHCET'S TRIALOptimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment. - BIO BEHÇET’S Behcets Disease
MedDRA version: 18.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Remicade
Product Name: Remicade
Product Code: 3400935113276
INN or Proposed INN: infliximab
Trade Name: Roferon-A, 3miu
Product Name: Roferon-A 3miu
Product Code: 8699505952864
INN or Proposed INN: alpha interferon
Trade Name: Roferon-A, 4.5miu
Product Name: Roferon-A, 4.5miu
Product Code: J1081
INN or Proposed INN: alpha interferon
Trade Name: Roferon-A, 6miu
Product Name: Roferon-A, 6miu
Product Code: 2387066
INN or Proposed INN: alpha interferon
The University of LiverpoolNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 3United Kingdom